Skip to main content
. 2021 Apr 24;6:165. doi: 10.1038/s41392-021-00568-6

Fig. 3.

Fig. 3

CVL218 binds to the nucleocapsid protein of SARS-CoV-2 (SARS-CoV-2-N). ae Kinetic analyses of the binding between SARS-CoV-2-N and the tested drugs, including CVL218 (a), PJ-34 (b), olaparib (c), remdesivir (d), and arbidol (e), measured by a SPR-based Biacore instrument. The derived dissociation constants between SARS-CoV-2-N and the tested drugs (CVL218 and PJ-34) are also shown